epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-512, Phase III. Recruitment complete

Moderate to severe ulcerative colitis

WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Woodgrove Biologics (fictional), Phase III, Immunology and GI. Month 0 is September 2021.
Randomise 471 (drop-out 15%) and screen about 906 (screen failure 48%)
Sep 2024
Confidence wanted
Sites per country
Edit the site counts in the table below
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Apr 2026month 55.2
  • Fast case (P10)Apr 2025month 43.9
  • Slow case (P90)Aug 2027month 71.4
  • Chance of meeting the deadline1%wanted 85%
  • Sites7010% likely to recruit nobody
  • Patients to screen906to randomise 471

Likely to finish in April 2026, 19 months after the deadline

EPI-512, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow caseActual
Sep 20210000
Mar 20222101
Sep 202237251629
Mar 2023110805779
Sep 2023192144103140
Mar 2024277207150192
Sep 2024360269196261
Mar 2025443333242316
Sep 2025471395288380
Mar 2026471458336448
Sep 2026471471381–
Mar 2027471471427–
Sep 2027471471471–
Mar 2028471471471–

Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.

How likely is it to finish by a given month?

Almost no chance of finishing by September 2024

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 1 of 100 dots finish in time

Drag the handle or
In time: 1%Median Apr 2026 · 1 dot not complete by Mar 2028Late: 99%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
Sep 20210%
Mar 20220%
Sep 20220%
Mar 20230%
Sep 20230%
Mar 20240%
Sep 20241%
Mar 20256%
Sep 202522%
Mar 202645%
Sep 202668%
Mar 202782%
Sep 202790%
Mar 202895%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.113
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×0.75 United States
  • Site type: ×0.988 Usual mix in United States
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 4.1 to 10.2 100107
United Kingdom
0.127
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.975 Usual mix in United Kingdom
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 4.0 to 10.0 4448
Spain
0.149
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×1 Spain
  • Site type: ×0.977 Usual mix in Spain
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 7.6 to 13.6 7165
Poland
0.220
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×1.4 Poland
  • Site type: ×1.028 Usual mix in Poland
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 11.1 to 17.1 41140
Turkey
0.148
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×1 Turkey
  • Site type: ×0.965 Usual mix in Turkey
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 1853
India
0.160
  • Therapeutic area: 0.300 Immunology and GI baseline
  • Country: ×1.1 India
  • Site type: ×0.952 Usual mix in India
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 1558

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Turkey

Four sourced risks

  • All sites

    Ethics committees fell from 145 to 49 in 2024, cutting review capacity.

    Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B

    Tightens: site activation overdue

  • All sites

    A fixed pharmaceutical exchange rate has caused repeated medicine shortages.

    Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D

    Tightens: study drug at the site

  • All sites

    Start-up time has not been measured since CRO data from 2014 and 2015.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

  • If it recurs

    Sites in the south-east lie in the 2023 earthquake zone.

    Major earthquake in a site region · SH-11 · grade C

India

Two sourced risks

  • All sites

    Vulnerable participants in trials of new drugs need an audio-visual record of their consent.

    Mandatory audio-visual consent for all participants · RW-03 · grade C

    Tightens: consent findings

  • All sites

    Start-up time is unmeasured beyond the statutory 90 working days.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

    Tightens: site activation overdue

Risk-register entries; the choice of entries per country is epiClinical's.